Working… Menu

Prospective Randomized Trial Between Needle Fasciotomy and Xiapex for Dupuytrens Contracture (PNFvsxiapex)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02476461
Recruitment Status : Recruiting
First Posted : June 19, 2015
Last Update Posted : June 19, 2015
Information provided by (Responsible Party):
Oslo University Hospital

Brief Summary:
The purpose of this study is to investigate whether percutaneous needle fasciotomy is as effective for treating Dupuytrens contracture as Xiapex. Immidiate treatment effect is to be investigated, as iskontracture size after 5 years. Contracture size after one and three years, and subjective hand function is also to be investigated.

Condition or disease Intervention/treatment Phase
Dupuytrens Contracture Drug: xiapex Procedure: percutaneous needle fasciotomy Phase 4

Detailed Description:

Prospective randomized study between Percutanous Needle Fasciotomy and Xiapex for Dupuytrens contracture.

A total of 50 patiens are to be randomized to eighter percutaneous needle fasciotomy or Xiapex treatment.

The patients randomized to xiapex treatment are treated as described in the product manual. Extentin treatment after one day.

The patients randomized to percutaneous needle fasciotomy are treated with the cutting teqnique: A littel quaddle local anestesia (xylocaine with adrenaline) is to be injected subcutant over the cord. After thet we use a 19G needle to cut the cord sufficient number sites to extend the finger.

The patients will be follwed up at 3 weeks, 3 months, 1 year, 3 years and 5 years. Investigators record contracture size, quicq-DASH, pain (VAS) and hand disability (VAS) pretreatment and at all controlls. At 3 weeks investigators register procedure complain. Side effects and complications, and advere effects are also to be investigated.

Our hypothesis is that it is no difference between the two methods in regard of contracture size after five years.

Inclution criteria: Symptomatic primary Dupuytrens contracture with palpable cord in one to three fingers, involving MCP, and total contracture size is over 30 degrees. Patient age over 18 years.

Exclution criteria:

Previously treated Dupuytrens contracture in the same hand more than tree affected fingers we will not include thumbs Other symptomatic injury or disease influencingf hand function ASA>3 Expected lifetime less than five years tetracycline treatment within two weeks pregnancy nursing allergy to clostridium histolyticum concmittent other clinical trial

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Prospektiv Randomisert Sammenlikning Mellom Percutan nålefasciotomi og Xiapex for Dupuytrens Kontraktur
Study Start Date : April 2015
Estimated Primary Completion Date : April 2016
Estimated Study Completion Date : January 2021

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: xiapex
1: xiapex: 0,58 mg clostridium histolyticum administered in the dupuytrens cord as discribed in producers manual
Drug: xiapex
Other Name: clostridium histolyticum

Experimental: PNF
percutaneous needle fasciotomi is performed at affected cords
Procedure: percutaneous needle fasciotomy
Other Name: PNF

Primary Outcome Measures :
  1. contracture size (degrees) [ Time Frame: five years ]

Secondary Outcome Measures :
  1. contracture size [ Time Frame: post treatment ]
    Contracture size mesured in degrees in each finger joint

Other Outcome Measures:
  1. contracture size (degrees) [ Time Frame: one year ]
    contracture size mesured in degrees in each finger joint

  2. contracture size (degrees) [ Time Frame: three years ]
    contracture size mesured in degrees in each finger joint

  3. quick-Dash [ Time Frame: one, three and five years ]
    Quick-DASH functional score measured in points.

  4. Pain [ Time Frame: one, three, five years ]
    Visual Analogue score

  5. Hand disability [ Time Frame: oen, three, five years ]
    Visual Analogue score

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • symptomatic Dupuytrens contracture with palpable cord, involving MCP, total contracture size over 30 degrees

Exclusion Criteria:

  • previous treated dupuytrens contracture same hand
  • more than tree fingers involvement
  • we will not include thumbs
  • other things affecting hand function
  • ASA>3
  • expected to live under five years
  • Tetracycline treatment within two weeks
  • pregnancy
  • nursing
  • allergy to clostridium histolyticum
  • participant in other trial

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02476461

Layout table for location contacts
Contact: hallgeir bratberg, MD +4790578848

Layout table for location information
Oslo Universitetssykehus Recruiting
Oslo, Norway, 0424
Contact: hallgeir bratberg, MD    +4790578848   
Sponsors and Collaborators
Oslo University Hospital
Layout table for investigator information
Principal Investigator: hallgeir bratberg, MD Oslo University Hospital

Layout table for additonal information
Responsible Party: Oslo University Hospital Identifier: NCT02476461     History of Changes
Other Study ID Numbers: 1234
First Posted: June 19, 2015    Key Record Dates
Last Update Posted: June 19, 2015
Last Verified: April 2015
Keywords provided by Oslo University Hospital:
percutanepus needle fasciotomy
clostridium histolyticum
Additional relevant MeSH terms:
Layout table for MeSH terms
Dupuytren Contracture
Joint Diseases
Musculoskeletal Diseases
Muscular Diseases
Neoplasms, Fibrous Tissue
Neoplasms, Connective Tissue
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Connective Tissue Diseases